FDA has questions about accuracy of 2 colon cancer screening tools

The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests which use DNA from a patient's stool to detect dangerous tumors and growths. FDA scientists have questions about the accuracy and the potential real-world impact of the kits from Epigenomics and Exact Sciences, according to briefing documents posted online. The agency released its reviews of the tests ahead of a two-day meeting. Read more here.